Organization (Hospital)
Cancer Treatment Centers of America
ClinicalTrials.gov lists Cancer Treatment Centers of America as lead sponsor of 41 trials, counting the companies grouped under it. Cancer Treatment Centers of America itself has 5 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Cancer Treatment Centers of America and 3 companies grouped under it: 41 lead-sponsored trials (2 its own, 39 in the grouped companies) and 4 legal-entity registrations (1 its own, 3 in the grouped companies).
Companies grouped under this page (3)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Western Regional Medical Center | 23 | 1 |
| Midwestern Regional Medical Center | 9 | 1 |
| Eastern Regional Medical Center | 7 | 1 |
Disease areas (74)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Breast Neoplasms | 11 |
| Colorectal Neoplasms | 4 |
| Lung Neoplasms | 4 |
| Hodgkin Disease | 3 |
| Kidney Neoplasms | 3 |
Showing 5 of 74 disease areas.
Trials by start year as sponsor or collaborator (3)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2014 | 1 |
| 1998 | 1 |
| 1997 | 1 |
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (5)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Sargramostim | 1 |
| Aldesleukin | 1 |
| DOCETAXEL | 1 |
| CARBOPLATIN | 1 |
| Ifosfamide | 1 |
Journals published in (5)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMC cancer | 1 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 1 |
| Clinical oncology (Royal College of Radiologists (Great Britain)) | 1 |
| Endoscopy | 1 |
| Investigational new drugs | 1 |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| TSPC America, Inc. | Co sponsors trial with | 1 |
Latest dated events (48)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2024-12-17 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2022-06-08 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2018-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2017-07-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2017-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 48 events.
CLIA clinical laboratory certificates (3)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| CANCER TREATMENT CENTERS OF AMERICA | Certificate of accreditation | Terminated |
| CANCER TREATMENT CENTERS OF AMERICA | Certificate of waiver | Terminated |
| CANCER TREATMENT CENTERS OF AMERICA | Certificate of waiver | Terminated |
Biomarker capability evidence (4)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ESR1 | Trial collaborator | Named in trial inclusion criteria |
| BRCA1 | Trial collaborator | Named in trial exclusion criteria |
| BRCA1 | Trial collaborator | Mentioned in trial text |
| ESR1 | Trial collaborator | Mentioned in trial text |
Biomarkers this organization publishes on (75)
Shown in this order: most publications first.
Showing 5 of 75 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.